{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T04:08:45Z","timestamp":1749787725458,"version":"3.41.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Glioblastoma multiform (GBM) is a primary brain malignancy resistant to conventional therapies, with poor survival. Cancer testis antigens (CTAs) are important cancer diagnostic biomarkers and therapeutic targets. Bioinformatics analysis of GBM clinical and molecular data was undertaken to identify and validate the key CTA genes, whose expression correlates with the survival of GBM patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>RNA-seq data of GBM were downloaded from TCGA and CGGA databases to analyze differentially expressed genes (DEGs). Cancer Testis genes (from the CT database), found up and down-regulated in the GBM series compared to normal samples, were determined in both TCGA and CGGA databases. Overall survival (OS) of GBM patients in the TCGA and CGGA databases as a function of the expression of key CTA genes was considered to identify those whose expression significantly predicts patient survival. The predictive values of our candidate genes were then tested using our independent cohort (n\u2009=\u200929) using an RT-qPCR approach.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Compared to normal brain samples, a total of 2463 and, 6249 up- and 3706 and, 6606 down-regulated genes were found in the TCGA and CGGA, respectively. The intersection between 279 CTAs in the CD database and the up-and-down-regulated genes of both other databases was found in 11 and 8 CTAs, respectively. Using tumor samples from our cohort of 29 patients and an RT-qPCR approach, we found that FBXO39 and CEP55 genes were highly expressed in GBM and that their expression predicted the OS (P\u2009&lt;\u20090.05).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our results support the potential use of FBXO39 and CEP55 gene expression measurement as prognostic biomarkers in GBM patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0326054","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T17:39:53Z","timestamp":1749749993000},"page":"e0326054","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer\/testis antigens FBXO39 and CEP55 expression correlates with survival in GBM patients"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6934-8908","authenticated-orcid":true,"given":"Parisa","family":"Azimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Bazrgar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taravat","family":"Yazdanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Totonchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abolhassan","family":"Ahmadiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"issue":"8","key":"pone.0326054.ref001","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"DN Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"pone.0326054.ref002","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"QT Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"issue":"10","key":"pone.0326054.ref003","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of glioblastoma multiforme-literature review","volume":"14","author":"S Grochans","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"pone.0326054.ref004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000522611","article-title":"Long-term time series forecasting and updates on survival analysis of glioblastoma multiforme: a 1975-2018 population-based study","volume":"56","author":"G Alexopoulos","year":"2022","journal-title":"Neuroepidemiology"},{"issue":"1","key":"pone.0326054.ref005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jocn.2010.04.050","article-title":"A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival","volume":"18","author":"P Das","year":"2011","journal-title":"J Clin Neurosci"},{"issue":"8","key":"pone.0326054.ref006","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1101\/gad.187922.112","article-title":"Emerging insights into the molecular and cellular basis of glioblastoma","volume":"26","author":"GP Dunn","year":"2012","journal-title":"Genes Dev"},{"issue":"4","key":"pone.0326054.ref007","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41568-022-00544-4","article-title":"Mechanisms driving the immunoregulatory function of cancer cells","volume":"23","author":"A van Weverwijk","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"pone.0326054.ref008","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"LG Almeida","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"pone.0326054.ref009","first-page":"1","article-title":"The cancer\/testis genes: review, standardization, and commentary","volume":"4","author":"MJ Scanlan","year":"2004","journal-title":"Cancer Immun"},{"issue":"1","key":"pone.0326054.ref010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gpb.2020.10.005","article-title":"Chinese Glioma Genome Atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients","volume":"19","author":"Z Zhao","year":"2021","journal-title":"Genom Proteom Bioinform"},{"key":"pone.0326054.ref011","doi-asserted-by":"crossref","first-page":"154090","DOI":"10.1016\/j.prp.2022.154090","article-title":"FBXO39 predicts poor prognosis and correlates with tumor progression in cervical squamous cell carcinoma","volume":"238","author":"Y Yang","year":"2022","journal-title":"Pathol Res Pract"},{"issue":"9","key":"pone.0326054.ref012","article-title":"Aberrant expression of cancer-testis antigen FBXO39 in breast cancer and its clinical significance","volume":"66","author":"YC Liu","year":"2020","journal-title":"Clin Lab"},{"issue":"2","key":"pone.0326054.ref013","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bbrc.2011.02.077","article-title":"Identification of BCP-20 (FBXO39) as a cancer\/testis antigen from colon cancer patients by SEREX","volume":"408","author":"M-H Song","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"pone.0326054.ref014","doi-asserted-by":"crossref","first-page":"154168","DOI":"10.1016\/j.prp.2022.154168","article-title":"The cancer-testis antigen FBXO39 predicts poor prognosis and is associated with stemness and aggressiveness in glioma","volume":"239","author":"J Wu","year":"2022","journal-title":"Pathol Res Pract"},{"issue":"1","key":"pone.0326054.ref015","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12890-023-02452-1","article-title":"CEP55: an immune-related predictive and prognostic molecular biomarker for multiple cancers","volume":"23","author":"G-S Li","year":"2023","journal-title":"BMC Pulm Med"},{"issue":"3","key":"pone.0326054.ref016","article-title":"Gene-based cancer-testis antigens as prognostic indicators in hepatocellular carcinoma","volume":"9","author":"Y Xu","year":"2023","journal-title":"Heliyon"},{"issue":"4","key":"pone.0326054.ref017","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/15384047.2017.1416934","article-title":"MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55","volume":"19","author":"Y Yin","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"pone.0326054.ref018","doi-asserted-by":"crossref","first-page":"4139320","DOI":"10.1155\/2020\/4139320","article-title":"Upregulation of CEP55 predicts dismal prognosis in patients with liver cancer","volume":"2020","author":"L Yang","year":"2020","journal-title":"Biomed Res Int"},{"key":"pone.0326054.ref019","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fgene.2020.00045","article-title":"Identification of core gene expression signature and key pathways in colorectal cancer","volume":"11","author":"X Ding","year":"2020","journal-title":"Front Genet"},{"issue":"2","key":"pone.0326054.ref020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.prp.2018.11.016","article-title":"Correlation between EZH2 and CEP55 and lung adenocarcinoma prognosis","volume":"215","author":"S Wu","year":"2019","journal-title":"Pathol Res Pract"},{"key":"pone.0326054.ref021","doi-asserted-by":"crossref","first-page":"6581576","DOI":"10.1155\/2019\/6581576","article-title":"Identification of potential biomarkers in glioblastoma through bioinformatic analysis and evaluating their prognostic value","volume":"2019","author":"Y Zhou","year":"2019","journal-title":"Biomed Res Int"},{"key":"pone.0326054.ref022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.neulet.2019.04.038","article-title":"CEP55 promoted the migration, invasion and neuroshpere formation of the glioma cell line U251","volume":"705","author":"F Li","year":"2019","journal-title":"Neurosci Lett"},{"issue":"4","key":"pone.0326054.ref023","first-page":"4789","article-title":"CEP55 promotes cell proliferation and inhibits apoptosis via the PI3K\/Akt\/p21 signaling pathway in human glioma U251 cells","volume":"15","author":"F Li","year":"2018","journal-title":"Oncol Lett"},{"issue":"2","key":"pone.0326054.ref024","first-page":"2700","article-title":"Overexpression of centrosomal protein 55 regulates the proliferation of glioma cell and mediates proliferation promoted by EGFRvIII in glioblastoma U251 cells","volume":"15","author":"H Zhu","year":"2018","journal-title":"Oncol Lett"},{"issue":"6","key":"pone.0326054.ref025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/ijo.2023.5519","article-title":"Cancer testis antigen subfamilies: attractive targets for therapeutic vaccine (Review)","volume":"62","author":"S Ren","year":"2023","journal-title":"Int J Oncol"},{"issue":"2","key":"pone.0326054.ref026","first-page":"799","article-title":"Identification of potential biomarkers in cancer testis antigens for glioblastoma","volume":"15","author":"F Li","year":"2023","journal-title":"Am J Transl Res"},{"key":"pone.0326054.ref027","doi-asserted-by":"crossref","first-page":"1198557","DOI":"10.3389\/fmolb.2023.1198557","article-title":"Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer","volume":"10","author":"X Xie","year":"2023","journal-title":"Front Mol Biosci"},{"issue":"4","key":"pone.0326054.ref028","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-23-1498","article-title":"Glioblastoma: not just another cancer","volume":"14","author":"HA Fine","year":"2024","journal-title":"Cancer Discov"},{"issue":"4","key":"pone.0326054.ref029","first-page":"733","article-title":"A review of methods for mapping and prediction of inventory attributes for operational forest management","volume":"60","author":"KD Brosofske","year":"2014","journal-title":"For Sci"},{"key":"pone.0326054.ref030","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1109\/IEMBS.2006.260828","article-title":"Overlapping probabilities of top ranking gene lists, hypergeometric distribution, and stringency of gene selection criterion","volume":"2006","author":"W Fury","year":"2006","journal-title":"Conf Proc IEEE Eng Med Biol Soc"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T17:40:16Z","timestamp":1749750016000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326054"}},"subtitle":[],"editor":[{"given":"Qinghua","family":"Shi,","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0326054","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}